Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Musto, P
Right arrow Articles by Carotenuto, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Musto, P
Right arrow Articles by Carotenuto, M
Haematologica, Vol 82, Issue 3, 354-356
Copyright © 1997 by Ferrata Storti Foundation

Clinical Trial

All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma

P Musto, MR Sajeva, G Sanpaolo, G D'Arena, PR Scalzulli, and M Carotenuto

Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo, Italy.

The in vitro inhibitory effect of all-trans retinoic acid (ATRA) on myeloma cell growth may be synergistically potentiated by the activity of dexamethasone (DEX) and alpha-interferon (IFN). We treated 10 patients with advanced, refractory multiple myeloma (MM) using a combination of ATRA (100 mg p.o., once a day for two weeks every month), DEX (40 mg i.v., for 4 days every 4 weeks) and IFN (3 MU s.c., three times a week). Eight patients completed at least three months of treatment and were evaluable for response. Two of them showed a partial response which persists after 15 to 17 months. Three patients experienced a stable plateau phase of 4 to +11 months, with a significant improvement in the performance status and bone pain. Progressive disease was seen in the remaining three patients. We conclude that the association of ATRA, DEX and IFN warrants further consideration in MM patients.


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Aviles, M. J. Nambo, N. Neri, E. Murillo, C. Castaneda, S. Cleto, A. Talavera, and M. Gonzalez
Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patientswith multiple myeloma
Ann. Onc., February 1, 2005; 16(2): 219 - 221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1997 by the Ferrata Storti Foundation.